Table 70.

Recommendations and Levels of Evidence for Prophylactic Therapeutic Intervention for Recurrent Tachyarrhythmias due to WPW Syndrome in Pediatric Patients

	COR	LOE	GOR (MINDS)	LOE (MINDS)
Patients with aborted sudden cardiac death, syncope or decreased cardiac function, and body weight ≥15 kg
Catheter ablation	I	C	C1	V
Use of Class IC drugs (e.g., flecainide)	IIa	C	C1	V
Use of β‐blockers	IIb	C	C2	VI
Patients with recurrent persistent SVT induced on electrophysiology study, or palpitations, and body weight ≥15 kg
Catheter ablation	I	C	C1	V
Use of Class IC drugs	I	C	C1	V
Use of sotalol	IIa	C	C1	V
Use of amiodarone	IIb	C	C2	VI
Patient with recurrent and/or symptomatic SVT, and body weight <15 kg
Use of Class IC drugs	I	C	B	IVa
Use of sotalol, Class IA drugs (e.g., disopyramide)	IIa	C	C1	V
Use of β‐blocker, amiodarone	IIb	C	C1	V
Catheter ablation	IIb	C	C1	V
Asymptomatic patient
Arrhythmic drug therapy	III	C	D	V

Abbreviations: COR, class of recommendation; GOR, grade of recommendation; LOE, level of evidence; MINDS, Medical Information Network Distribution Service; SVT, supraventricular tachycardia; WPW, Wolff‐Parkinson‐White.